Community-based Primary Care Program Effects on Pharmacotherapy of Type 2 Diabetes and Hypertension in Peru
NCT ID: NCT05979142
Last Updated: 2023-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
131 participants
OBSERVATIONAL
2011-09-30
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question\[s\] it aims to answer are:
* Compared to pre-program usual care, does the program result in greater benefits, measured as greater proportions of patients with glucose and blood pressure control or maximal quantities and doses of medications?
* Are there greater benefits when the program was provided at home compared to when the program was provided in a clinic?
* Does longer participation in the program result in greater benefits?
Participants will participate in:
* Self-management education provided by community health workers.
* Monitoring of healthy behaviors and glucose, blood pressure, and weight.
* Receipt of free medications for blood pressure, glucose, and heart disease prevention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Clinical Pharmacist-Led Intervention on Management of Diabetic Hypertensive Patients in Eastern Nepal
NCT05707481
A Trial to De-prescribe Inappropriate Medications in the Community Dwelling Elderly
NCT02053194
Multi-PAP: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy
NCT02866799
Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program
NCT00916214
MultiPAP Plus: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy
NCT04147130
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Three binary exposures were evaluated for their effects on adherence to four treatment standards and one composite standard: 1) 'program exposure' (post- vs. pre-exposure); 2) 'program retention in care' (\>50% of allowable time in both home and clinic care periods, compared to \<50% in either care period (but not both)), and 3) 'care period', (clinic compared to home care). 'Care period treatment time' (\>50% of allowable time versus less) was evaluated as an independent variable in the study of the care period exposure.
During the pre-exposure period, usual care was provided by two public hospitals, several Ministry of Health clinics, private clinics and pharmacies, and Siempre Salud. The program, to which patients were then exposed, had components of four CCM elements (delivery system design, self-management, decision support, and community resources), CHWs, and no out-of-pocket costs for visits and medications. Self-management was based on national standards and utilized educational materials from professional societies and government agencies in the USA. Decision support consisted of guidelines-based standards adapted to our low-resource setting and simplified medication treatment protocols for diabetes, hypertension, and primary prevention of CVD. The delivery system consisted of two care models employed sequentially: first home care, then clinic care (see care period exposure).
During the home care period, the physician made an initial visit, after which CHWs made weekly visits to patients' homes. CHWs monitored clinical parameters, provided self-management education and support, tracked self-care behaviors, documented visits, acted on clinical alerts, and delivered medications. They entered encounter data into a spreadsheet and filled prescriptions under physician supervision. The physician made treatment decisions reliant on home visit data and patient care conferences. During the subsequent clinic period, patients made monthly visits to the clinic physician who provided all care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
program (pre-exposure)
During the pre-exposure period, usual care was provided by two public hospitals, several Ministry of Health clinics, private clinics and pharmacies, and Siempre Salud.
No interventions assigned to this group
program (post-exposure)
The program had components of four Chronic Care Model (CCM) elements (delivery system design, self-management, decision support, and community resources), community health workers (CHWs), and no out-of-pocket costs for visits and medications.
community-based primary care program
See group description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
community-based primary care program
See group description
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Arizona
OTHER
Asociación Siempre Salud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John E Deaver, MD
Role: PRINCIPAL_INVESTIGATOR
Asociación Siempre Salud
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1912252903
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.